Quantbot Technologies LP Lowers Stock Position in Boston Scientific Co. (NYSE:BSX)

Quantbot Technologies LP decreased its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 39.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 80,021 shares of the medical equipment provider's stock after selling 52,202 shares during the quarter. Quantbot Technologies LP's holdings in Boston Scientific were worth $7,147,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the business. Millstone Evans Group LLC purchased a new stake in shares of Boston Scientific during the fourth quarter worth $52,000. HUB Investment Partners LLC grew its holdings in shares of Boston Scientific by 24.6% during the fourth quarter. HUB Investment Partners LLC now owns 4,289 shares of the medical equipment provider's stock worth $383,000 after buying an additional 846 shares in the last quarter. Whittier Trust Co. grew its holdings in shares of Boston Scientific by 4.4% during the fourth quarter. Whittier Trust Co. now owns 6,101 shares of the medical equipment provider's stock worth $545,000 after buying an additional 257 shares in the last quarter. Northwest & Ethical Investments L.P. grew its holdings in shares of Boston Scientific by 0.4% during the fourth quarter. Northwest & Ethical Investments L.P. now owns 74,428 shares of the medical equipment provider's stock worth $6,647,000 after buying an additional 330 shares in the last quarter. Finally, iA Global Asset Management Inc. grew its holdings in shares of Boston Scientific by 6.4% during the fourth quarter. iA Global Asset Management Inc. now owns 180,367 shares of the medical equipment provider's stock worth $16,110,000 after buying an additional 10,840 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company's stock.

Remove Ads

Analysts Set New Price Targets

BSX has been the subject of a number of analyst reports. Canaccord Genuity Group upped their price objective on shares of Boston Scientific from $98.00 to $101.00 and gave the company a "buy" rating in a report on Monday, December 9th. Stifel Nicolaus upped their price objective on shares of Boston Scientific from $100.00 to $115.00 and gave the company a "buy" rating in a report on Thursday, February 6th. Needham & Company LLC reissued a "hold" rating on shares of Boston Scientific in a report on Monday, March 3rd. Royal Bank of Canada upped their price objective on shares of Boston Scientific from $105.00 to $116.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. Finally, Wells Fargo & Company upped their price objective on shares of Boston Scientific from $100.00 to $118.00 and gave the company an "overweight" rating in a report on Thursday, February 6th. Two research analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $108.91.

Insider Buying and Selling

In other Boston Scientific news, CFO Daniel J. Brennan sold 67,333 shares of the stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $105.24, for a total value of $7,086,124.92. Following the transaction, the chief financial officer now directly owns 225,808 shares in the company, valued at $23,764,033.92. This represents a 22.97 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Jeffrey B. Mirviss sold 4,675 shares of the stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $104.25, for a total transaction of $487,368.75. Following the completion of the transaction, the executive vice president now owns 28,454 shares in the company, valued at $2,966,329.50. This represents a 14.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 137,302 shares of company stock worth $14,319,269. Company insiders own 0.50% of the company's stock.

Boston Scientific Stock Up 0.3 %

Shares of BSX stock traded up $0.27 during trading hours on Tuesday, reaching $99.17. 5,370,015 shares of the stock were exchanged, compared to its average volume of 5,742,343. The business's fifty day moving average is $101.21 and its two-hundred day moving average is $91.97. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. Boston Scientific Co. has a 12-month low of $66.16 and a 12-month high of $107.17. The firm has a market capitalization of $146.36 billion, a P/E ratio of 79.34, a P/E/G ratio of 2.79 and a beta of 0.77.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. As a group, research analysts expect that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.